Savior Lifetec Corporation (TPEX:4167)

Market Cap	7.23B +32.8%
Revenue (ttm)	1.12B -7.2%
Net Income	1.03B +124.9%
EPS	3.10 +129.6%
Shares Out	331.55M
PE Ratio	7.04
Forward PE	n/a
Dividend	0.75 (3.46%)
Ex-Dividend Date	Jul 28, 2026

Volume	1,296,356
Open	21.75
Previous Close	21.75
Day's Range	21.65 - 22.10
52-Week Range	15.64 - 23.95
Beta	0.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 10, 2026

About Savior Lifetec

Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally. The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms. It also provides medicine manufacturer technology and services. In addition, the company sells antibacterial raw materials and injectables. Savior Lifetec Corporation was founded in 1993 and is head...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 384
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4167

Financial Performance

In 2025, Savior Lifetec's revenue was 1.20 billion, a decrease of -1.28% compared to the previous year's 1.22 billion. Earnings were 537.45 million, an increase of 194.69%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error